Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
HIV Vaccine Trials Network
Study ID
NCT04403880
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Sample collection — OTHER
    * Optional nasal specimen(s) * Blood collection

Study Details

The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.

Key Dates

Start date
May 13, 2020
Status verified
Dec 2025
Primary completion
Apr 21, 2022
Completion
Apr 21, 2022

Study Design

Enrollment
760 participants (actual)

Arms

  • Arm: Group 1
    Persons not hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3 * 1A: Persons with asymptomatic infection, ages 18 through 55, inclusive * 1B: Persons with asymptomatic infection, age \> 55 * 1C: Persons with symptomatic infection (ie, COVID-19) ages 18 through 55 * 1D: Persons with symptomatic infection (ie, COVID-19), age \> 55
  • Arm: Group 2
    Persons previously hospitalized for COVID-19, without clinical spectrum or outcomes specified in group 3 * 2A: Persons 18 through 55 years of age * 2B: Persons \> 55 years of age
  • Arm: Group 3
    Persons with specific clinical spectrums or outcomes, regardless of hospitalization history (eg, persons recovered after intubation, with prolonged viral shedding, with myocarditis/pericarditis, with rapid recovery from COVID-19, with a second positive SARS-CoV-2 RT-PCR test result after a negative result)

Primary Outcome Measure

SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort [ Time Frame: Measured at Months 0, 2, 4 ]

Locations (21)

FacilityCityStateZIPSite coordinators
Alabama Vaccine CRSBirminghamAlabama35294-
UCLA CARE Center CRSLos AngelesCalifornia90035-
Bridge HIV CRSSan FranciscoCalifornia94143-
George Washington University CRSWashington D.C.District of Columbia20037-1894-
The Ponce de Leon Center CRSAtlantaGeorgia30308-2012-
The Hope Clinic of the Emory Vaccine Center CRSDecaturGeorgia30030-
Adolescent & Young Adult Research at The CORE Center (AYAR at CORE)ChicagoIllinois60612-
New Orleans Adolescent Trials Unit CRSNew OrleansLouisiana70112-
Johns Hopkins University CRSBaltimoreMaryland21205-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)BostonMassachusetts02115-6110-
Fenway Health Clinical Research Site CRSBostonMassachusetts02215-4302-
New Jersey Medical School Clinical Research Center CRSNewarkNew Jersey07103-
Columbia P&S CRSNew YorkNew York10032-3732-
Harlem Prevention Center CRSNew YorkNew York10027-
New York Blood Center CRSNew YorkNew York10065-
University of Rochester Vaccines to Prevent HIV Infection CRSRochesterNew York14642-
Bronx Prevention Research Center CRSThe BronxNew York10451-
Chapel Hill CRSChapel HillNorth Carolina27599-
Penn Prevention CRSPhiladelphiaPennsylvania19104-
Vanderbilt Vaccine CRSNashvilleTennessee37232-2582-
Seattle Vaccine and Prevention CRSSeattleWashington98109-1024-

Find similar trials in Birmingham, AL

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Alabama Vaccine CRS· Birmingham, ALUCLA CARE Center CRS· Los Angeles, CABridge HIV CRS· San Francisco, CAGeorge Washington University CRS· Washington D.C., DCThe Ponce de Leon Center CRS· Atlanta, GAThe Hope Clinic of the Emory Vaccine Center CRS· Decatur, GA

Related Studies